It depends on the standard you follow. As of September 2026, Insmed Incorporated (INSM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.83% / 30% · (Cash+Inv) / Mkt Cap (36m) 4.62% / 30% · Interest income / Revenue 2.11% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 2.83% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 4.62% / 33% · Receivables / Mkt Cap (36m) 1.04% / 49% · Interest income / Revenue 2.11% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 2.83% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 4.62% / 33.33% · Receivables / Mkt Cap (24m) 1.04% / 33.33% · Interest income / Revenue 2.11% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 31.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 57.2% / 33.33% · Receivables / Avg Assets (4Q) 9.16% / 33.33% · Interest income / Revenue 2.11% / 5% | Fail |
| FTSE | Debt / Total Assets 31.5% / 33.33% · (Cash+ST Inv) / Total Assets 51.5% / 33.33% · (Cash+Recv) / Total Assets 63.2% / 33.33% · Interest income / Revenue 2.11% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Insmed Incorporated (INSM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. Insmed Incorporated is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.11% of each dividend: Insmed Incorporated's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Insmed Incorporated (NASDAQ: INSM) is a Healthcare company (Biotechnology) with a market capitalization of $27.0B. The Maz Rating grades it against the other companies in its sector.
Insmed Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $122.88, Insmed Incorporated trades at 17.7x sales and 37.0x book value. Over the last twelve months it generated about $1.5B of revenue and a net loss of $619M. It runs a gross margin of 84.3%, an operating margin of -35.6% and a net margin of -39.9%. It shows return on equity of -82.7%, return on invested capital of -32.8% and a free cash flow yield of -2.4%. On the balance sheet: a debt-to-equity ratio of 1.02 and a current ratio of 2.86. Over the past 52 weeks the share price ranged from $90.39 to $212.75, with a beta of 0.81.
Insmed Incorporated does not currently pay a dividend.
36 Wall Street analyst ratings cover the stock: 33 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.